Keeping von Willebrand Factor under Control: Alternatives for ADAMTS13

被引:14
|
作者
Tersteeg, Claudia [1 ]
Fijnheer, Rob [2 ]
Pasterkamp, Gerard [2 ]
de Groot, Philip G. [2 ]
Vanhoorelbeke, Karen [1 ]
de Maat, Steven [2 ]
Maas, Coen [2 ]
机构
[1] Katholieke Univ Leuven, IRF Life Sci, Lab Thrombosis Res, Campus Kulak Kortrijk, Kortrijk, Belgium
[2] UMC Utrecht, Lab Clin Chem & Hematol, Heidelberglaan 100,G-03-550, NL-3584 CX Utrecht, Netherlands
来源
SEMINARS IN THROMBOSIS AND HEMOSTASIS | 2016年 / 42卷 / 01期
关键词
ADAMTS13; plasmin; VWF; thrombotic thrombocytopenic purpura; thrombotic microangiopathy; THROMBOTIC THROMBOCYTOPENIC PURPURA; NEUTROPHIL EXTRACELLULAR TRAPS; UROKINASE RECEPTOR EXPRESSION; TISSUE-PLASMINOGEN-ACTIVATOR; FACTOR-CLEAVING PROTEASE; DNA TRAPS; VONWILLEBRAND-FACTOR; EMERGENCY BYPASS; DISEASE-ACTIVITY; FACTOR MULTIMERS;
D O I
10.1055/s-0035-1564838
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Von Willebrand factor (VWF) is one of the most important proteins of the hemostatic system. Its multimeric state is essential for its natural function to guide platelets to sites of injury. ADAMTS13 is the key protease that regulates the multimeric state of VWF. Without ADAMTS13, VWF multimers can grow to pathologically large sizes. This is a risk factor for the life-threatening condition thrombotic thrombocytopenic purpura (TTP). In this condition, VWF-rich thrombi occlude the microvasculature of various tissues. Intriguingly, a complete ADAMTS13 deficiency does not cause continuous TTP, either in patients or genetically targeted mice. Instead, TTP occurs in episodes of disease, separated by extended periods of remission. This indicates that regulating factors beyond ADAMTS13 are likely involved in this pathologic cascade of events. This raises the question of what really happens when ADAMTS13 is (temporarily) unavailable. In this review, we explore the possible role of complementary mechanisms that are capable of modifying the thrombogenic potential of VWF.
引用
收藏
页码:9 / 17
页数:9
相关论文
共 50 条
  • [31] Identification of ADAMTS13 peptide sequences binding to von Willebrand factor
    Moriki, Takanori
    Maruyama, Ichiro N.
    Igari, Atsuko
    Ikeda, Yasuo
    Murata, Mitsuru
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2010, 391 (01) : 783 - 788
  • [32] The Intriguing Connections between von Willebrand Factor, ADAMTS13 and Cancer
    Colonne, Chanukya K.
    Favaloro, Emmanuel J.
    Pasalic, Leonardo
    HEALTHCARE, 2022, 10 (03)
  • [33] ADAMTS13 and von Willebrand factor and the risk of myocardial infarction in men
    Chion, Chan K. N. K.
    Doggen, Carine J. M.
    Crawley, James T. B.
    Lane, David A.
    Rosendaal, Frits R.
    BLOOD, 2007, 109 (05) : 1998 - 2000
  • [34] Characterization of von Willebrand factor and ADAMTS13 in plasma derived factor concentrates
    Konkle, B. A.
    Fletcher, S. N.
    Lannert, K. W.
    Johnsen, J. M.
    Bergman, G. E. G.
    Teramura, G.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2013, 11 : 311 - 312
  • [35] Von Willebrand Factor, ADAMTS13, and the Risk of Mortality The Rotterdam Study
    Sonneveld, Michelle A. H.
    Franco, Oscar H.
    Ikram, M. Arfan
    Hofman, Albert
    Kavousi, Maryam
    de Maat, Moniek P. M.
    Leebeek, Frank W. G.
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2016, 36 (12) : 2446 - 2451
  • [36] Biological variations of ADAMTS13 and von Willebrand factor in human adults
    Kilercik, Meltem
    Coskun, Abdurrahman
    Serteser, Mustafa
    Inan, Deniz
    Unsal, Ibrahim
    BIOCHEMIA MEDICA, 2014, 24 (01) : 138 - 145
  • [37] Von Willebrand factor, ADAMTS13 and the risk of mortality: the rotterdam study
    Sonneveld, M. A. H.
    Ikram, M. A.
    Kavousi, M.
    Hofman, A.
    Franco, O. H.
    Leebeek, F. W.
    de Maat, M. P.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 65 - 65
  • [38] Von Willebrand Factor and ADAMTS13 A Candidate Couple for Preeclampsia Pathophysiology
    Stepanian, Alain
    Cohen-Moatti, Marie
    Sanglier, Thibaut
    Legendre, Paulette
    Ameziane, Nejma
    Tsatsaris, Vassilis
    Mandelbrot, Laurent
    de Prost, Dominique
    Veyradier, Agnes
    ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2011, 31 (07) : 1703 - 1709
  • [39] The middle and distal carboxyl terminal domains of ADAMTS13 are critical for docking ADAMTS13 to von Willebrand factor.
    Zhang, Ping
    Weilan, Pan
    Rux, Ann H.
    Sachais, Bruce S.
    Long Zheng, X.
    BLOOD, 2006, 108 (11) : 103A - 103A
  • [40] Evaluating the interaction of von Willebrand factor and ADAMTS13-and perhaps also beyond ADAMTS13
    Favaloro, Emmanuel J.
    THROMBOSIS RESEARCH, 2014, 134 (06) : 1167 - 1168